Recent advances in mucosal vaccines and adjuvants

Current Opinion in Immunology

Volumn 14, Issue 5, 2002, Pages 666-672

  Allison, James P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 18; VIRUS VACCINE;

CAMPYLOBACTER JEJUNI; CLOSTRIDIUM DIFFICILE; DIARRHEA; DRUG BINDING; DRUG EFFECT; DRUG SAFETY; ESCHERICHIA COLI; HELICOBACTER PYLORI; HERPES SIMPLEX VIRUS 2; HUMAN; IMMUNIZATION; INFLAMMATION; INFLUENZA; MUCOSA; MUCOSAL IMMUNITY; MYCOPLASMA PNEUMONIAE; NONHUMAN; REVIEW; ROTAVIRUS; SALMONELLA; SHIGELLA; SIDE EFFECT; TH1 CELL; TH2 CELL; VIBRIO CHOLERAE;

EID: 0036774999     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(02)00384-9     Document Type: Review

References (37)

1. Murphy T.V., Gargiullo P.M., Massoudi M.S., Nelson D.B., Jumaan A.O., Okoro C.A., Zanardi L.R., Setia S., Fair E., LeBaron C.W., et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med. 344:2001;564-572. A strong association between vaccination with the recently withdrawn tetravalent rhesus-human reassorted rotavirus vaccine and intussusception among otherwise healthy infants is shown. The authors predict that one case of intussusception would occur for each 5000-10 000 infants vaccinated.
2. Type 1 Diabetes Study Group . Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med. 346:2002;1685-1691.
3. Choy E.H., Scott D.L., Kingsley G.H., Thomas S., Murphy A.G., Staines N., Panayi G.S. Control of rheumatoid arthritis by oral tolerance. Arthritis Rheum. 44:2001;1993-1997.
4. Pizza M., Giuliani M.M., Fontana M.R., Monaci E., Douce G., Dougan G., Mills K.H., Rappuoli R., Del Giudice G. Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine. 19:2001;2534-2541.
5. Mowat A.M., Donachie A.M., Jagewall S., Schon K., Lowenadler B., Dalsgaard K., Kaastrup P., Lycke N. CTA1-DD-immune stimulating complexes: a novel, rationally designed combined mucosal vaccine adjuvant effective with nanogram doses of antigen. J Immunol. 167:2001;3398-3405. A combined mucosal adjuvant delivery system, CTA1-DD-ISCOMS, consisting of a cell-binding moiety (the Ig-binding D moiety of S. aureus), an enzymatically active component (the A1 subunit of CT), and a mucosal delivery system (ISCOMS) is described, which is successfully used for both nasal and oral vaccination. In the latter case, however, the doses required are numerous.
6. Haan L., Verweij W.R., Holtrop M., Brands R., van Scharrenburg G.J., Palache A.M., Agsteribbe E., Wilschut J. Nasal or intramuscular immunization of mice with influenza subunit antigen and the B subunit of Escherichia coli heat-labile toxin induces IgA- or IgG-mediated protective mucosal immunity. Vaccine. 19:2001;2898-2907.
7. Hagiwar Y., Tsuji T., Iwasaki T., Kadowaki S., Asanuma H., Chen Z., Komase K., Suzuki Y., Aizawa C., Kurata T., et al. Effectiveness and safety of mutant Escherichia coli heat-labile enterotoxin (LT H44A) as an adjuvant for nasal influenza vaccine. Vaccine. 19:2001;2071-2079.
8. McCluskie M.J., Weeratna R.D., Krieg A.M., Davis H.L. CpG DNA is an effective oral adjuvant to protein antigens in mice. Vaccine. 19:2000;950-957.
9. Gallichan W.S., Woolstencroft R.N., Guarasci T., McCluskie M.J., Davis H.L., Rosenthal K.L. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus- 2 in the genital tract. J Immunol. 166:2001;3451-3457. Intranasal vaccination of mice with HSV-1 glycoprotein B and CpG ODN adjuvant induced HSV-1/HSV-2 cross-protection and resistance to a genital HSV-2 challenge. The protection was associated with HSV-specific genital IgA, systemic CTL and mucosal CTL.
10. Staats H.F., Bradney C.P., Gwinn W.M., Jackson S.S., Sempowski G.D., Liao H.X., Letvin N.L., Haynes B.F. Cytokine requirements for induction of systemic and mucosal CTL after nasal immunization. J Immunol. 167:2001;5386-5394.
11. Eo S.K., Lee S., Kumaraguru U., Rouse B.T. Immunopotentiation of DNA vaccine against herpes simplex virus via co-delivery of plasmid DNA expressing CCR7 ligands. Vaccine. 19:2001;4685-4693.
12. Lilliard J.W.J., Boyaka P.N., Taub D.D., McGhee J.R. RANTES potentiates antigen-specific mucosal immune responses. J Immunol. 166:2001;162-169.
13. van Ginkel F.W., Jackson R.J., Yuki Y., McGhee J.R. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J Immunol. 165:2000;4778-4782. The authors show that intranasally administered CT targets the olfactory bulb and redirects co-administered proteins to the same site. This study is particularly interesting in view of the recently withdrawn human nasal influenza vaccine. This particular vaccine was administered together with LT (which is closely related to CT), which was associated with several instances of facial paresis among the vaccinees.
14. Simmons C.P., Hussell T., Sparer T., Walzl G., Openshaw P., Dougan G. Mucosal delivery of a respiratory syncytial virus CTL peptide with enterotoxin-based adjuvants elicits protective, immunopathogenic, and immunoregulatory antiviral CD8+ T cell responses. J Immunol. 166:2001;1106-1113. LT and a LT mutant lacking ADP-ribosyltransferase activity were shown to be strong adjuvants for intranasally administered RSV vaccines. The vaccination induced both RSV-specific CTL and protected against RSV challenge. However, administration of LT adjuvant was also associated with enhanced disease including lung eosinophilia.
15. Goetsch L., Gonzalez A., Plotnicky-Gilquin H., Haeuw J.F., Aubry J.P., Beck A., Bonnefoy J.Y., Corvaia N. Targeting of nasal mucosa-associated antigen-presenting cells in vivo with an outer membrane protein A derived from Klebsiella pneumoniae. Infect Immun. 69:2001;6434-6444.
16. Oh Y.K., Kim J.P., Hwang T.S., Ko J.J., Kim J.M., Yang J.S., Kim C.K. Nasal absorption and biodistribution of plasmid DNA: an alternative route of DNA vaccine delivery. Vaccine. 19:2001;4519-4525.
17. Singh M., Vajdy M., Gardner J., Briones M., O'Hagan D. Mucosal immunization with HIV-1 gag DNA on cationic microparticles prolongs gene expression and enhances local and systemic immunity. Vaccine. 20:2001;594-602.
18. Wu Y., Wang X., Csencsits K.L., Haddad A., Walters N., Pascual D.W. M cell-targeted DNA vaccination. Proc Natl Acad Sci USA. 98:2001;9318-9323. A reovirus vaccine was targeted to the apical surface of M cells through the conjugation of the vaccine component(s) to polylysine. Intranasal vaccination of mice with this vaccine induced both mucosal IgA and CTL responses.
19. Loehr B.I., Willson P., Babiuk L.A., van Drunen Littel-van den Hurk S. Gene gun-mediated DNA immunization primes development of mucosal immunity against bovine herpesvirus 1 in cattle. J Virol. 74:2000;6077-6086.
20. Wang S.W., Kozlowski P.A., Schmelz G., Manson K., Wyand M.S., Glickman R., Montefiori D., Lifson J.D., Johnson R.P., Neutra M.R., et al. Effective induction of simian immunodeficiency virus-specific systemic and mucosal immune responses in primates by vaccination with proviral DNA producing intact but noninfectious virions. J Virol. 74:2000;10514-10522.
21. Lundholm P., Leandersson A.C., Christensson B., Bratt G., Sandstrom E., Wahren B. DNA mucosal HIV vaccine in humans. Virus Res. 82:2002;141-145.
22. Grangette C., Muller-Alouf H., Goudercourt D., Geoffroy M.C., Turneer M., Mercenier A. Mucosal immune responses and protection against tetanus toxin after intranasal immunization with recombinant Lactobacillus plantarum. Infect Immun. 69:2001;1547-1553.
23. Li T., Takeda N., Miyamura T. Oral administration of hepatitis E virus-like particles induces a systemic and mucosal immune response in mice. Vaccine. 19:2001;3476-3484.
24. Niikura M., Takamura S., Kim G., Kawai S., Saijo M., Morikawa S., Kurane I., Li T.C., Takeda N., Yasutomi Y. Chimeric recombinant hepatitis E virus-like particles as an oral vaccine vehicle presenting foreign epitopes. Virology. 293:2002;273-280.
25. Guerrero R.A., Ball J.M., Krater S.S., Pacheco S.E., Clements J.D., Estes M.K. Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses. J Virol. 75:2001;9713-9722. The authors show that VLPs are immunogenic when administered at a mucosal surface. Recombinant Norwalk VLPs given nasally to mice induced strong mucosal IgA responses in the absence of any external adjuvant. Oral vaccination was less promising.
26. Shi W., Liu J., Huang Y., Qiao L. Papillomavirus pseudovirus: a novel vaccine to induce mucosal and systemic cytotoxic T-lymphocyte responses. J Virol. 75:2001;10139-10148. This paper shows that VLPs can be used as carriers/adjuvants for mucosal DNA vaccination. Oral vaccination with papillomavirus VLPs containing a DNA plasmid that encode for the regulatory papillomavirus protein E7 induced strong mucosal CTL responses and protected against challenge with an E7-expressing papillomavirus.
27. Gardner J.P., Frolov I., Perri S., Ji Y., MacKichan M.L., zur Megede J., Chen M., Belli B.A., Driver D.A., Sherrill S., et al. Infection of human dendritic cells by a sindbis virus replicon vector is determined by a single amino acid substitution in the E2 glycoprotein. J Virol. 74:2000;11849-11857.
28. Vajdy M., Gardner J., Neidleman J., Cuadra L., Greer C., Perri S., O'Hagan D., Polo J.M. Human immunodeficiency virus type 1 Gag-specific vaginal immunity and protection after local immunizations with sindbis virus-based replicon particles. J Infect Dis. 184:2001;1613-1616. Highly immunogenic, replication-defective, enveloped Sindbis virus vectors are described that can carry either foreign DNA and/or express foreign proteins. Vaginal or rectal vaccination of mice with sindbis-based replicon particles expressing HIV gag antigen protected mice against a vaginal challenge with vaccinia virus expressing the same HIV gag.
29. Johansson E.L., Wassen L., Holmgren J., Jertborn M., Rudin A. Nasal and vaginal vaccinations have differential effects on antibody responses in vaginal and cervical secretions in humans. Infect Immun. 69:2001;7481-7486.
30. Igietseme J.U., Murdin A. Induction of protective immunity against Chlamydia trachomatis genital infection by a vaccine based on major outer membrane protein-lipophilic immune response-stimulating complexes. Infect Immun. 68:2000;6798-6806.
31. Finerty S., Stokes C.R., Gruffydd-Jones T.J., Hillman T.J., Barr F.J., Harbour D.A. Targeted lymph node immunization can protect cats from a mucosal challenge with feline immunodeficiency virus. Vaccine. 20:2001;49-58.
32. Belyakov I.M., Ahlers J.D., Clements J.D., Strober W., Berzofsky J.A. Interplay of cytokines and adjuvants in the regulation of mucosal and systemic HIV-specific CTL. J Immunol. 165:2000;6454-6462.
33. Belyakov I.M., Hel Z., Kelsall B., Kuznetsov V.A., Ahlers J.D., Nacsa J., Watkins D.I., Allen T.M., Sette A., Altman J., et al. Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nat Med. 7:2001;1320-1326.
34. Sun J.B., Xiao B.G., Lindblad M., Li B.L., Link H., Czerkinsky C., Holmgren J. Oral administration of cholera toxin B subunit conjugated to myelin basic protein protects against experimental autoimmune encephalomyelitis by inducing transforming growth factor-beta-secreting cells and suppressing chemokine expression. Int Immunol. 12:2000;1449-1457.
35. Sun J.B., Stadecker M.J., Mielcarek N., Lakew M., Li B.L., Hernandez H.J., Czerkinsky C., Holmgren J. Nasal administration of Schistosoma mansoni egg antigen-cholera B subunit conjugate suppresses hepatic granuloma formation and reduces mortality in S. mansoni-infected mice. Scand J Immunol. 54:2001;440-447. The authors show that mucosal tolerance using CTB as a carrier protein can be used to treat infection-induced inflammatory pathology. Intranasal delivery of S. mansoni egg antigen conjugated to CTB reduced both liver granuloma formation and mortality in S. mansoni-infected mice.
36. Boirivant M., Fuss I.J., Ferroni L., De Pascale M., Strober W. Oral administration of recombinant cholera toxin subunit B inhibits IL-12-mediated murine experimental (trinitrobenzene sulfonic acid) colitis. J Immunol. 166:2001;3522-3532. This study shows that CTB is a powerful inhibitor of Th1-driven immunopathology. Oral administration of CTB given either before or after onset of trinitrobenzene sulfonic acid (TNBS)-induced colitits prevented and resolved colitis, respectively. CTB treatment was associated with a marked inhibition of IL-12 secretion which prevented the development of a TNBS-induced Th1/IFN-γ response.
37. Collins L.V., Eriksson K., Ulrich R.G., Tarkowski A. Mucosal tolerance to a bacterial superantigen indicates a novel pathway to prevent toxic shock. Infect Immun. 70:2002;2282-2287. Mucosal vaccination with superantigen can also prevent superantigen-induced toxic shock syndrome. Intranasal administration of staphylococcal enterotoxin A (SEA) protected mice against a later lethal systemic SEA challenge. The protection was associated with enhanced levels of systemic IL-10.